Results 171 to 180 of about 26,552 (294)

Associations Between Antidiabetic Pharmacotherapy and Hearing Thresholds in Adult Hearing‐Impaired Patients With Type 2 Diabetes

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who ...
Francesco Martines   +8 more
wiley   +1 more source

Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

open access: yesBMJ Open Diabetes Res Care
Sklepinski S   +13 more
europepmc   +1 more source

A Trp574–Leu substitution confers resistance to three classes of acetolactate synthase inhibitors in Australian brome grass (Bromus diandrus)

open access: yesPest Management Science, Volume 82, Issue 10, Page 9437-9443, October 2026.
Target‐site based imidazolinone resistance in brome grass was found to be conferred by a mutation at position 574 in the ALS gene and to severely impact the efficacy of the herbicide Intervix®, a co‐formulation of imazamox and imazapyr. Abstract BACKGROUND Brome grass (Bromus diandrus) is a prevalent weed in southern Australian cropping regions which ...
Roberto Busi   +5 more
wiley   +1 more source

Pro‐197 mutations confer resistance to thiencarbazone but not to foramsulfuron in ALS‐resistant Poa annua populations

open access: yesPest Management Science, Volume 82, Issue 10, Page 10134-10146, October 2026.
Foramsulfuron remains effective on Pro‐197 Poa annua, but co‐formulation with thiencarbazone reduces efficacy due to limited activity and antagonism. Therefore, foramsulfuron + thiencarbazone should be used in fields without ALS‐resistant weeds to ensure effective in‐crop control.
Vijaya Bhaskar Alwarnaidu Vijayarajan   +6 more
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli   +3 more
wiley   +1 more source

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9607-9620, October 2026.
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy